| 3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers | 07/08 07:45 | investorplace.com |
| Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules | 05/16 23:45 | prnewswire.com |
| Seelos Therapeutics Announces 1-for-8 Reverse Stock Split | 05/14 11:45 | prnewswire.com |
| Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations | 04/29 08:00 | prnewswire.com |
| Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose) | 03/19 08:15 | prnewswire.com |
| Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules | 01/26 08:30 | prnewswire.com |
| Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002 | 01/22 08:00 | prnewswire.com |
| Therapy's New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution | 01/09 13:56 | investorplace.com |
| Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024 | 01/02 08:00 | prnewswire.com |
| Seelos Therapeutics, Inc. Releases Letter to its Stockholders | 12/22 08:00 | prnewswire.com |